# A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC

> **NCT06769295** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 28 (estimated)

## Conditions studied

- Lung Cancer, Non-Small Cell

## Interventions

- **DRUG:** AK112

## Key facts

- **NCT ID:** NCT06769295
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2025-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06769295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06769295, "A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06769295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*